Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2010, Article ID 535612, 13 pages
http://dx.doi.org/10.1155/2010/535612
Review Article

Lipid Disturbances in Psoriasis: An Update

1Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, ul. Radziwillowska 13, 20-080 Lublin, Poland
2Department of Dermatology, Venereology and Allergology, Wrocław Medical University and Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. R. Weigla 12, 53-114 Wrocław, Poland

Received 12 April 2010; Accepted 10 June 2010

Academic Editor: Giuseppe Valacchi

Copyright © 2010 Aldona Pietrzak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Icen, C. S. Crowson, M. T. McEvoy, F. J. Dann, S. E. Gabriel, and H. M. Kremers, “Trends in incidence of adult-onset psoriasis over three decades: a population-based study,” Journal of the American Academy of Dermatology, vol. 60, no. 3, pp. 394–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. F. C. Wilson, M. Icen, C. S. Crowson, M. T. McEvoy, S. E. Gabriel, and H. M. Kremers, “Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study,” Arthritis Care and Research, vol. 61, no. 2, pp. 233–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. V. Chandran and S. P. Raychaudhuri, “Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis,” Journal of Autoimmunity, vol. 34, no. 3, pp. J314–J321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Romanowska, N. Al Yacoub, H. Seidel et al., “PPARδ enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor,” Journal of Investigative Dermatology, vol. 128, no. 1, pp. 110–124, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. Y.-J. Chen, J.-L. Shen, C.-Y. Wu, Y.-T. Chang, C.-M. Chen, and F.-Y. Lee, “Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis,” Journal of the American Academy of Dermatology, vol. 60, no. 2, pp. 225–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Nijsten and M. Wakkee, “Complexity of the association between psoriasis and comorbidities,” Journal of Investigative Dermatology, vol. 129, no. 7, pp. 1601–1603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Pietrzak, K. Janowski, J. Łopatynski et al., “Psoriasis and heart. Something new under the sun,” Giornale Italiano di Dermatologia e Venereologia, vol. 141, no. 5, pp. 457–463, 2006. View at Google Scholar · View at Scopus
  8. A. Pietrzak, B. Lecewicz-Toruń, and G. Kądziela-Wypyska, “Changes in the digestive system in patients suffering from psoriasis,” Annales Universitatis Mariae Curie-Sklodowska. Sectio D, vol. 53, pp. 187–194, 1998. View at Google Scholar · View at Scopus
  9. M. Chibowska, “Role of serum lipids in pseriasis,” Przeglad Dermatologiczny, vol. 57, no. 2, pp. 255–260, 1970. View at Google Scholar · View at Scopus
  10. A. Pietrzak, B. Toruniowa, B. Pietrzak, and J. Chwaluk, “Lipid profile in psoriatic patients according to sex and age,” Przeglad Dermatologiczny, vol. 81, no. 5, pp. 441–449, 1994. View at Google Scholar
  11. A. Pietrzak, I. Jastrzebska, D. Krasowska et al., “Serum pancreatic lipase [EC 3.1.1.3] activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis,” Journal of Molecular Catalysis B, vol. 40, no. 3-4, pp. 144–154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. D. I. Wilkinson, “Lipid metabolism in psoriasis,” in Proceedings of the International Symposium on Psoriasis, E. M. Farber, A. J. Cox, and P. H. Jacobs, Eds., pp. 277–287, Stanford University Press, Stanford, Calif, USA, 1971. View at Google Scholar
  13. M. Yamaoka-Tojo, T. Tojo, R. Kosugi et al., “Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia,” Lipids in Health and Disease, vol. 8, p. 41, 2009. View at Google Scholar
  14. R. Zawydiwski, D. L. Sprecher, M. J. Evelegh, P. Horsewood, C. Carte, and M. Patterson, “A novel test for the measurement of skin cholesterol,” Clinical Chemistry, vol. 47, no. 7, pp. 1302–1304, 2001. View at Google Scholar · View at Scopus
  15. J. H. Stein, W. S. Tzou, J. M. DeCara et al., “Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the predictor of advanced subclinical atherosclerosis study),” American Journal of Cardiology, vol. 101, no. 7, pp. 986–991, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Mallbris, F. Granath, A. Hamsten, and M. Ståhle, “Psoriasis is associated with lipid abnormalities at the onset of skin disease,” Journal of the American Academy of Dermatology, vol. 54, no. 4, pp. 614–621, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Ishikawa and H. Sato, “Demonstration of beta-lipoproteins in the psoriatic skin by immunofluorescent technique,” Archiv für Dermatologische Forschung, vol. 30, no. 8, pp. 191–206, 1974. View at Google Scholar
  18. N. S. Tekin, I. O. Tekin, F. Barut, and E. Y. Sipahi, “Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients,” Mediators of Inflammation, vol. 2007, Article ID 78454, 5 pages, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Pietrzak, G. Chodorowska, J. Szepietowski, A. Zalewska-Janowska, D. Krasowska, and J. Hercogová, “Psoriasis and serum lipid abnormalities,” Dermatologic Therapy, vol. 23, no. 2, pp. 160–173, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Jungersted, L. I. Hellgren, G. B. E. Jemec, and T. Agner, “Lipids and skin barrier function—a clinical perspective,” Contact Dermatitis, vol. 58, no. 5, pp. 255–262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. O. Bleck, D. Abeck, J. Ring et al., “Two ceramide subfractions detectable in Cer(AS) position by HPTLC in skin surface lipids of non-lesional skin of atopic eczema,” Journal of Investigative Dermatology, vol. 113, no. 6, pp. 894–900, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Landmann, “Epidermal permeability barrier: transformation of lamellar granule-disks into intercellular sheets by a membrane-fusion process, a freeze-fracture study,” Journal of Investigative Dermatology, vol. 87, no. 2, pp. 202–209, 1986. View at Google Scholar · View at Scopus
  23. P. M. Elias and G. K. Menon, “Structural and lipid biochemical correlates of the epidermal permeability barrier,” Advances in Lipid Research, vol. 24, pp. 1–26, 1991. View at Google Scholar · View at Scopus
  24. S. Grayson and P. M. Elias, “Isolation and lipid biochemical characterization of stratum corneum membrane complexes: implications for the cutaneous permeability barrier,” Journal of Investigative Dermatology, vol. 78, no. 2, pp. 128–135, 1982. View at Google Scholar · View at Scopus
  25. M. Q. M. Man, K. R. Feingold, C. R. Thornfeldt, and P. M. Elias, “Optimization of physiological lipid mixtures for barrier repair,” Journal of Investigative Dermatology, vol. 106, no. 5, pp. 1096–1101, 1996. View at Google Scholar · View at Scopus
  26. W. M. Holleran, K. R. Feingold, M. Q. M. Man, W. N. Gao, J. M. Lee, and P. M. Elias, “Regulation of epidermal sphingolipid synthesis by permeability barrier function,” Journal of Lipid Research, vol. 32, no. 7, pp. 1151–1158, 1991. View at Google Scholar · View at Scopus
  27. S. Motta, M. Monti, S. Sesana, L. Mellesi, R. Ghidoni, and R. Caputo, “Abnormality of water barrier function in psoriasis: role of ceramide fractions,” Archives of Dermatology, vol. 130, no. 4, pp. 452–456, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Ghadially, J. T. Reed, and P. M. Elias, “Stratum corneum structure and function correlates with phenotype in psoriasis,” Journal of Investigative Dermatology, vol. 107, no. 4, pp. 558–564, 1996. View at Google Scholar · View at Scopus
  29. B. S. Khyshiktuev and E. V. Falko, “Alterations in the parameters of lipid metabolism in different biological objects in psoriatic patients during exacerbation and remission,” Vestnik Dermatologii i Venerologii, vol. 6, pp. 40–43, 2005. View at Google Scholar
  30. V. Ansidei, M. Binazzi, A. Cantelmi, A. Gaiti, and G. Porcellati, “Phospholipid involvement in psoriatic epidermis,” Italian Journal of Biochemistry, vol. 30, no. 1, pp. 40–45, 1981. View at Google Scholar
  31. E. S. Fortinskaia, T. I. Torkhovskaia, G. I. Sharapova, T. K. Loginova, Z. I. Kliuchnikova, and E. M. Khalilov, “Features of distribution of free and esterified cholesterol in the epidermis, biological membranes and plasma lipoproteins in psoriasis,” Klinicheskaia Laboratornaia Diagnostika, no. 4, pp. 38–43, 1996. View at Google Scholar · View at Scopus
  32. B. S. Khyshiktuyev, T. M. Karavayeva, and Ye. V. Falko, “Variability of quantitative changes in short-chain fatty acids in the serum and epidermis in psoriasis,” Klinichescheskaya Laboratornaya Diagnostika, no. 8, pp. 22–24, 2008. View at Google Scholar · View at Scopus
  33. F. R. Maxfield and I. Tabas, “Role of cholesterol and lipid organization in disease,” Nature, vol. 438, no. 7068, pp. 612–621, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. C. E. Orfanos, “Scanning electron microscopy in psoriasis,” in Proceedings of the International Symposium on Psoriasis, E. M. Farber, A. J. Cox, and P. H. Jacobs, Eds., pp. 169–185, Stanford University Press, Stanford, Calif, USA, 1971. View at Google Scholar
  35. D. Tsambaos, A. Kalofoutis, and J. Stratigos, “Thin-layer chromatography of phospholipid components of normal and psoriatic epidermis,” British Journal of Dermatology, vol. 97, no. 2, pp. 135–138, 1977. View at Google Scholar · View at Scopus
  36. M. Wakkee, Psoriasis: comorbidity and treatment, Doctoral thesis, Erasmus University Rotterdam, Rotterdam, The Netherlands, 2010.
  37. M. Ponec, L. Havekes, J. Kempenaar, and B. J. Vermeer, “Cultured human skin fibroblasts and keratinocytes: differences in the regulation of cholesterol synthesis,” Journal of Investigative Dermatology, vol. 81, no. 2, pp. 125–130, 1983. View at Google Scholar · View at Scopus
  38. M. Farshchian, A. Zamanian, M. Farshchian, A.-R. Monsef, and H. Mahjub, “Serum lipid level in Iranian patients with psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 21, no. 6, pp. 802–805, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Gisondi, G. Tessari, A. Conti et al., “Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study,” British Journal of Dermatology, vol. 157, no. 1, pp. 68–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. A. D. Cohen, M. Sherf, L. Vidavsky, D. A. Vardy, J. Shapiro, and J. Meyerovitch, “Association between psoriasis and the metabolic syndrome: a cross-sectional study,” Dermatology, vol. 216, no. 2, pp. 152–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. L.-S. Tam, B. Tomlinson, T. T.-W. Chu et al., “Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation,” Rheumatology, vol. 47, no. 5, pp. 718–723, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Ferretti, O. Simonetti, A. M. Offidani et al., “Changes of plasma lipids and erythrocyte membrane fluidity in psoriatic children,” Pediatric Research, vol. 33, no. 5 I, pp. 506–509, 1993. View at Google Scholar · View at Scopus
  43. P. Rocha-Pereira, A. Santos-Silva, I. Rebelo, A. Figueiredo, A. Quintanilha, and F. Teixeira, “Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease,” Clinica Chimica Acta, vol. 303, no. 1-2, pp. 33–39, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Akhyani, A. H. Ehsani, R. M. Robati, and A. M. Robati, “The lipid profile in psoriasis: a controlled study,” Journal of the European Academy of Dermatology and Venereology, vol. 21, no. 10, pp. 1330–1332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. Z. Javidi, N. T. Meibodi, and Y. Nahidi, “Serum lipids abnormalities and psoriasis,” Indian Journal of Dermatology, vol. 52, no. 2, pp. 89–92, 2007. View at Google Scholar · View at Scopus
  46. T. Amin, E. Saied, and S. H. Abdou, “Atherosclerotic risk in psoriasis,” Journal of Pan-Arab League of Dermatologists, vol. 16, no. 2, pp. 39–45, 2005. View at Google Scholar
  47. D. R. Bajaj, S. M. Mahesar, B. R. Devrajani, and M. P. Iqbal, “Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad,” Journal of the Pakistan Medical Association, vol. 59, no. 8, pp. 512–515, 2009. View at Google Scholar · View at Scopus
  48. C. Reynoso-von Drateln, E. Martínez-Abundis, B. R. Balcázar-Muñoz, R. Bustos-Saldaña, and M. González-Ortiz, “Lipid profile, insulin secretion, and insulin sensitivity in psoriasis,” Journal of the American Academy of Dermatology, vol. 48, no. 6, pp. 882–885, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Piskin, F. Gurkok, G. Ekuklu, and M. Senol, “Serum lipid levels in psoriasis,” Yonsei Medical Journal, vol. 44, no. 1, pp. 24–26, 2003. View at Google Scholar · View at Scopus
  50. A. Örem, G. Çimşit, O. Değer, C. Örem, and B. Vanizor, “The significance of autoantibodies against oxidatively modified low-density lipoprotein (LDL) in patients with psoriasis,” Clinica Chimica Acta, vol. 284, no. 1, pp. 81–88, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Vanizor Kural, A. Örem, G. U. Çimşit, Y. E. Yandi, and M. Calapoǧlu, “Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis,” Clinica Chimica Acta, vol. 328, no. 1-2, pp. 71–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Coimbra, H. Oliveira, F. Reis et al., “Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease,” Journal of Dermatological Science, vol. 55, no. 3, pp. 202–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Hadas, A. Bożek, and J. Jarząb, “Impact of phototherapy on selected lipid profile indices in psoriatic patients allowing for intensification of the disease,” Postępy Dermatologii i Alergologii, vol. 24, no. 5, pp. 215–223, 2007. View at Google Scholar · View at Scopus
  54. A. Toker, M. Kadi, A. K. Yildirim, H. Aksoy, and F. Akçay, “Serum lipid profile paraoxonase and arylesterase activities in psoriasis,” Cell Biochemistry and Function, vol. 27, no. 3, pp. 176–180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Kuliszkiewicz-Janus, A. S. Mohamed, and N. Abod, “The biology of HDL lipoprotein and its antisclerotic activity,” Postepy Higieny i Medycyny Doświadczalnej, vol. 60, pp. 307–315, 2006. View at Google Scholar · View at Scopus
  56. T. F. Daniels, K. M. Killinger, J. J. Michal, R. W. Wright Jr., and Z. Jiang, “Lipoproteins, cholesterol homeostasis and cardiac health,” International Journal of Biological Sciences, vol. 5, no. 5, pp. 474–488, 2009. View at Google Scholar · View at Scopus
  57. G. B. Niestierienko, G. H. Kogon, and F. D. Ulanowska, “Lipidnyj obmien u bolnych sizmienieniami kostno-sustawnowo apparata pri psoriaticzieskoj boliezni,” Vestnik Dermatologii i Venerologii, vol. 6, p. 31, 1971. View at Google Scholar
  58. B. T. Wilienczik, “Frakcji fosfolipidow syworotki krowi bolnych psoriazom i egziemoj,” Vestnik Dermatologii i Venerologii, vol. 6, p. 71, 1971. View at Google Scholar
  59. T. S. Panfilova and G. V. Tananova, “Lipid metabolic indices of children with psoriasis,” Vestnik Dermatologii i Venerologii, no. 6, pp. 60–61, 1983. View at Google Scholar · View at Scopus
  60. C. Vahlquist, B. Berne, and M. Boberg, “The fatty-acid spectrum in plasma and adipose tissue in patients with psoriasis,” Archives of Dermatological Research, vol. 278, no. 2, pp. 114–119, 1985. View at Google Scholar · View at Scopus
  61. I. P. Iwanowa and T. E. Mariejewa, “Naruszienija pierieisnowo okislienija lipidow aktiwnosti lizosomalnych gidrolaz i ich korriekcja u bolnych psoriazom,” Vestnik Dermatologii i Venerologii, vol. 4, p. 26, 1987. View at Google Scholar
  62. M. Chibowska, Biochemical studies of serum lipids and histochemical studies on lipids of the soft palate mucosa in palatal lipidophilia and psoriasis with associated prelipidophilia, Doctoral thesis, Klinika Dermatologii Akademii Medycznej w Lublinie, Lublin, Poland, 1967.
  63. S. I. Dowzanski, W. N. Szierstniewa, and I. G. Graszkina, “Sierdieczno sosudiataja sistiema i lipidnyjobmien u bolnych psoriazom,” Vestnik Dermatologii i Venerologii, vol. 17, 1982. View at Google Scholar
  64. G. Mingrone, A. V. Greco, A. Venier, E. Peruzzi, and F. Serri, “Lipid synthesis from the liver in patients with psoriasis,” Archives of Dermatological Research, vol. 268, no. 3, pp. 271–276, 1980. View at Google Scholar · View at Scopus
  65. S. Brenner, A. Krakowski, O. Levtov, D. Heldenberg, B. Werbin, and I. Tamir, “Serum lipids in patients with psoriasis,” Dermatologica, vol. 150, p. 196, 1975. View at Google Scholar
  66. E. Campalani, M. H. Allen, D. Fairhurst et al., “Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin,” British Journal of Dermatology, vol. 154, no. 2, pp. 345–352, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Karpouzis, R. Caridha, G. Tripsianis, C. Michailidis, G. Martinis, and S. V. Veletza, “Apolipoprotein e gene polymorphism in psoriasis,” Archives of Dermatological Research, vol. 301, no. 6, pp. 405–410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Miyauchi, “Immunohistochemical study for the localization of apolipoprotein AI, B100, and E in normal and psoriatic skin,” Igaku Kenkyu. Acta Medica, vol. 61, no. 2, pp. 79–86, 1991. View at Google Scholar · View at Scopus
  69. P. G. Frank and Y. L. Marcel, “Apolipoprotein A-I: structure-function relationships,” Journal of Lipid Research, vol. 41, no. 6, pp. 853–872, 2000. View at Google Scholar · View at Scopus
  70. R. Barbaras, P. Puchois, J.-C. Fruchart, and G. Ailhaud, “Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles,” Biochemical and Biophysical Research Communications, vol. 142, no. 1, pp. 63–69, 1987. View at Google Scholar · View at Scopus
  71. P. J. Blanche, E. L. Gong, T. M. Forte, and A. V. Nichols, “Characterization of human high-density lipoproteins by gradient gel electrophoresis,” Biochimica et Biophysica Acta, vol. 665, no. 3, pp. 408–419, 1981. View at Google Scholar · View at Scopus
  72. W. V. Brown and M. L. Baginsky, “Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein,” Biochemical and Biophysical Research Communications, vol. 46, no. 2, pp. 375–382, 1972. View at Google Scholar · View at Scopus
  73. R. M. Krauss, P. N. Herbert, R. I. Levy, and D. S. Fredrickson, “Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins,” Circulation Research, vol. 33, no. 4, pp. 403–411, 1973. View at Google Scholar · View at Scopus
  74. P. K. J. Kinnunen and C. Ehnholm, “Effect of serum and C apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase,” FEBS Letters, vol. 65, no. 3, pp. 354–357, 1976. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Windler and R. J. Havel, “Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver,” Journal of Lipid Research, vol. 26, no. 5, pp. 556–565, 1985. View at Google Scholar · View at Scopus
  76. A. Pietrzak, J. Kądzielewski, K. Janowski et al., “Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity,” International Journal of Dermatology, vol. 48, no. 4, pp. 379–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. T. Xiao, C. Yang, Y. Xiao, and F. Song, “Serum apolipoprotein levels of psoriatic patients with normal serum lipid levels,” Chinese Medical Sciences Journal, vol. 12, no. 4, pp. 224–228, 1997. View at Google Scholar · View at Scopus
  78. M. Seishima, M. Seishima, S. Mori, and A. Noma, “Serum lipid and apolipoprotein levels in patients with psoriasis,” British Journal of Dermatology, vol. 130, no. 6, pp. 738–742, 1994. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Barba, D. Schena, S. Ferrari, and L. Grigolini, “Observations on lipid metabolism in patients affected with psoriasis. Preliminary findings,” Giornale Italiano di Dermatologia e Venereologia, vol. 122, no. 3, pp. 85–89, 1987. View at Google Scholar · View at Scopus
  80. T. P. Leren, K. Maartmann-Moe, P. Thune, and K. Berg, “Low density lipoprotein receptors in cultured skin fibroblasts from psoriasis patients,” Clinical Genetics, vol. 25, no. 3, pp. 230–241, 1984. View at Google Scholar · View at Scopus
  81. F. Oliveiro, P. Sfriso, G. Baldo et al., “Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis,” Clinical and Experimental Rheumatology, vol. 27, no. 1, pp. 79–83, 2009. View at Google Scholar · View at Scopus
  82. R. W. Mahley, “Apolipoprotein E: cholesterol transport protein with expanding role in cell biology,” Science, vol. 240, no. 4852, pp. 622–630, 1988. View at Google Scholar · View at Scopus
  83. R. W. Mahley and S. C. Rall Jr., “Apolipoprotein E: far more than a lipid transport protein,” Annual Review of Genomics and Human Genetics, vol. 1, no. 2000, pp. 507–537, 2000. View at Google Scholar · View at Scopus
  84. H. Furumoto, K. Nakamura, T. Imamura et al., “Association of apolipoprotein allele ε2 with psoriasis vulgaris in Japanese population,” Archives of Dermatological Research, vol. 289, no. 9, pp. 497–500, 1997. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Coto-Segura, E. Coto, V. Alvarez, and J. Santos-Juanes, “Apolipoprotein ε4 allele is associated with psoriasis severity: reply,” Archives of Dermatological Research, vol. 302, no. 3, pp. 237–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. A. A. Geronikaki and A. M. Gavalas, “Antioxidants and inflammatory disease: synthetic and natural antioxidants with anti-inflammatory activity,” Combinatorial Chemistry and High Throughput Screening, vol. 9, no. 6, pp. 425–442, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Rashmi, K. S. J. Rao, and K. H. Basavaraj, “A comprehensive review of biomarkers in psoriasis,” Clinical and Experimental Dermatology, vol. 34, no. 6, pp. 658–663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Briganti and M. Picardo, “Antioxidant activity, lipid peroxidation and skin diseases. What's new,” Journal of the European Academy of Dermatology and Venereology, vol. 17, no. 6, pp. 663–669, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Nassiri, F. Malekzad, M. Sarlak et al., “Interplay among antioxidants and oxidants in psoriasis,” Iranian Journal of Dermatology, vol. 12, pp. 56–59, 2009. View at Google Scholar
  90. M. Yildirim, H. S. Inaloz, V. Baysal, and N. Delibas, “The role of oxidants and antioxidants in psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 17, no. 1, pp. 34–36, 2003. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Campanati, O. Simonetti, B. Silvestri et al., “Anticardiolipin antibodies expression in psoriasis,” Giornale Italiano di Dermatologia e Venereologia, vol. 139, no. 3, pp. 165–170, 2004. View at Google Scholar · View at Scopus
  92. I. Kökçam and M. Nazıroǧlu, “Antioxidants and lipid peroxidation status in the blood of patients with psoriasis,” Clinica Chimica Acta, vol. 289, no. 1-2, pp. 23–31, 1999. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Naziroglu and I. Kokcam, “Antioxidants and lipid peroxidation status in the blood of patients with alopecia,” Cell Biochemistry and Function, vol. 18, no. 3, pp. 169–173, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. S. M. Lynch, A. L. Campione, and M. K. Moore, “Plasma thiols inhibit hemin-dependent oxidation of human low-density lipoprotein,” Biochimica et Biophysica Acta, vol. 1485, no. 1, pp. 11–22, 2000. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Thambyrajah and J. N. Townend, “Homocysteine and atherothrombosis—mechanisms for injury,” European Heart Journal, vol. 21, no. 12, pp. 967–974, 2000. View at Publisher · View at Google Scholar · View at Scopus
  96. B. Vanizor Kural, A. Örem, G. Çimşit, H. A. Uydu, Y. E. Yandi, and A. Alver, “Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients,” Clinica Chimica Acta, vol. 332, no. 1-2, pp. 23–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Peus, A. Beyerle, H. L. Rittner et al., “Anti-psoriatic drug anthralin activates JNK via lipid peroxidation: mononuclear cells are more sensitive than keratinocytes,” Journal of Investigative Dermatology, vol. 114, no. 4, pp. 688–692, 2000. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Westergaard, J. Henningsen, C. Johansen et al., “Expression and localization of peroxisome proliferator-activated receptors and nuclear factor κB in normal and lesional psoriatic skin,” Journal of Investigative Dermatology, vol. 121, no. 5, pp. 1104–1117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. D. A. Plager, A. A. Leontovich, S. A. Henke et al., “Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications,” Experimental Dermatology, vol. 16, no. 1, pp. 28–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Schmuth, Y. J. Jiang, S. Dubrac, P. M. Elias, and K. R. Feingold, “Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology,” Journal of Lipid Research, vol. 49, no. 3, pp. 499–509, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. D. M. Sommer, S. Jenisch, M. Suchan, E. Christophers, and M. Weichenthal, “Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis,” Archives of Dermatological Research, vol. 298, no. 7, pp. 321–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. M.-H. Tan, M. Gordon, O. Lebwohl, J. George, and M. G. Lebwohl, “Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor α monoclonal antibody,” Archives of Dermatology, vol. 137, no. 7, pp. 930–933, 2001. View at Google Scholar · View at Scopus
  103. M. Schmuth, C. M. Haqq, W. J. Cairns et al., “Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes,” Journal of Investigative Dermatology, vol. 122, no. 4, pp. 971–983, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Q. M. Man, E.-H. Choi, M. Schmuth et al., “Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing,” Journal of Investigative Dermatology, vol. 126, no. 2, pp. 386–392, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Dubrac, P. Stoitzner, D. Pirkebner et al., “Peroxisome proliferator-activated receptor-α activation inhibits Langerhans cell function,” Journal of Immunology, vol. 178, no. 7, pp. 4362–4372, 2007. View at Google Scholar · View at Scopus
  106. A. J. Fowler, M. Y. Sheu, M. Schmuth et al., “Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production,” Journal of Investigative Dermatology, vol. 120, no. 2, pp. 246–255, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. S. B. Joseph, A. Castrillo, B. A. Laffitte, D. J. Mangelsdorf, and P. Tontonoz, “Reciprocal regulation of inflammation and lipid metabolism by liver X receptors,” Nature Medicine, vol. 9, no. 2, pp. 213–219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. C. N. Ellis, J. Varani, G. J. Fisher et al., “Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-γ inhibit keratinocyte proliferation,” Archives of Dermatology, vol. 136, no. 5, pp. 609–616, 2000. View at Google Scholar · View at Scopus
  109. H. A. Pershadsingh, S. C. Benson, and C. N. Ellis, “Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient,” Skinmed, vol. 4, no. 6, pp. 386–390, 2005. View at Google Scholar · View at Scopus
  110. T. Bongartz, B. Coras, T. Vogt, J. Schölmerich, and U. Müller-Ladner, “Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: an open-label pilot study,” Rheumatology, vol. 44, no. 1, pp. 126–129, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. H. Robertshaw and P. S. Friedmann, “Pioglitazone: a promising therapy for psoriasis,” British Journal of Dermatology, vol. 152, no. 1, pp. 189–191, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. N. Shafiq, S. Malhotra, P. Pandhi, M. Gupta, B. Kumar, and K. Sandhu, “Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6),” International Journal of Dermatology, vol. 44, no. 4, pp. 328–333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. S. Kuenzli and J.-H. Saurat, “Effect of topical PPARβ/δ and PPARγ agonists on plaque psoriasis: a pilot study,” Dermatology, vol. 206, no. 3, pp. 252–256, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Kuenzli and J.-H. Saurat, “Peroxisome proliferator-activated receptors as new molecular targets in psoriasis,” Current Drug Targets: Inflammation & Allergy, vol. 3, no. 2, pp. 205–211, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Denda, L. C. Wood, S. Emami et al., “The epidermal hyperplasia associated with repeated barrier disruption by acetone treatment or tape stripping cannot be attributed to increased water loss,” Archives of Dermatological Research, vol. 288, no. 5-6, pp. 230–238, 1996. View at Publisher · View at Google Scholar · View at Scopus
  116. L. Piqueras, A. R. Reynolds, K. M. Hodivala-Dilke et al., “Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 63–69, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. S. G. Harris and R. P. Phipps, “Induction of apoptosis in mouse T cells upon peroxisome proliferator-activated receptor gamma (PPAR-γ) binding,” Advances in Experimental Medicine and Biology, vol. 507, pp. 421–425, 2002. View at Google Scholar · View at Scopus
  118. S. Kuenzli and J.-H. Saurat, “Peroxisome proliferator-activated receptors in cutaneous biology,” British Journal of Dermatology, vol. 149, no. 2, pp. 229–236, 2003. View at Publisher · View at Google Scholar · View at Scopus
  119. S. Malhotra, D. Bansal, N. Shafiq, P. Pandhi, and B. Kumar, “Potential therapeutic role of peroxisome proliferator activated receptor-γ agonists in psoriasis,” Expert Opinion on Pharmacotherapy, vol. 6, no. 9, pp. 1455–1461, 2005. View at Publisher · View at Google Scholar · View at Scopus
  120. L. G. Kömüves, M. Schmuth, A. J. Fowler et al., “Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-β in murine epidermis,” Journal of Investigative Dermatology, vol. 118, no. 1, pp. 25–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  121. H. Yalcin, D. D. Balci, E. Ucar et al., “Myocardial perfusion is preserved in patients with psoriasis without clinically evident cardiovascular disease,” Journal of the European Academy of Dermatology and Venereology, vol. 23, no. 7, pp. 798–802, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. Y. B. Brauchli, S. S. Jick, M. Miret, and C. R. Meier, “Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis,” British Journal of Dermatology, vol. 160, no. 5, pp. 1048–1056, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Mastrolonardo, A. Picardi, D. Alicino, A. Bellomo, and P. Pasquini, “Cardiovascular reactivity to experimental stress in psoriasis: a controlled investigation,” Acta Dermato-Venereologica, vol. 86, no. 4, pp. 340–344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. M. J. Kaplan, “Cardiometabolic risk in psoriasis: differential effects of biologic agents,” Vascular Health and Risk Management, vol. 4, no. 6, pp. 1229–1235, 2008. View at Google Scholar · View at Scopus
  125. R. S. Azfar and J. M. Gelfand, “Psoriasis and metabolic disease: epidemiology and pathophysiology,” Current Opinion in Rheumatology, vol. 20, no. 4, pp. 416–422, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. H. M. Kremers, M. T. McEvoy, F. J. Dann, and S. E. Gabriel, “Heart disease in psoriasis,” Journal of the American Academy of Dermatology, vol. 57, no. 2, pp. 347–354, 2007. View at Publisher · View at Google Scholar · View at Scopus
  127. P. Gisondi, F. Fantin, M. Del Giglio et al., “Chronic plaque psoriasis is associated with increased arterial stiffness,” Dermatology, vol. 218, no. 2, pp. 110–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Dreiher, D. Weitzman, J. Shapiro, B. Davidovici, and A. D. Cohen, “Psoriasis and chronic obstructive pulmonary disease: a case-control study,” British Journal of Dermatology, vol. 159, no. 4, pp. 956–960, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. J. M. Gelfand, A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis, and A. B. Troxel, “Risk of myocardial infarction in patients with psoriasis,” Journal of the American Medical Association, vol. 296, no. 14, pp. 1735–1741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. M. D. Herron, M. Hinckley, M. S. Hoffman et al., “Impact of obesity and smoking on psoriasis presentation and management,” Archives of Dermatology, vol. 141, no. 12, pp. 1527–1534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  131. C. Huerta, E. Rivero, and L. A. García Rodríguez, “Incidence and risk factors for psoriasis in the general population,” Archives of Dermatology, vol. 143, no. 12, pp. 1559–1565, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. J. A. Kaye, L. Li, and S. S. Jick, “Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis,” British Journal of Dermatology, vol. 159, no. 4, pp. 895–902, 2008. View at Publisher · View at Google Scholar · View at Scopus
  133. R. J. Ludwig, C. Herzog, A. Rostock et al., “Psoriasis: a possible risk factor for development of coronary artery calcification,” British Journal of Dermatology, vol. 156, no. 2, pp. 271–276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis, A. B. Troxel, and J. M. Gelfand, “Prevalence of cardiovascular risk factors in patients with psoriasis,” Journal of the American Academy of Dermatology, vol. 55, no. 5, pp. 829–835, 2006. View at Publisher · View at Google Scholar · View at Scopus
  135. J. M. Gelfand, E. D. Dommasch, D. B. Shin et al., “The risk of stroke in patients with psoriasis,” Journal of Investigative Dermatology, vol. 129, no. 10, pp. 2411–2418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. W. Koenig, “Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein,” International Journal of Cardiology, vol. 98, no. 2, pp. 199–206, 2005. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Corbetta, R. Angioni, A. Cattaneo, P. Becke-Peccoz, and A. Spada, “Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines,” European Journal of Endocrinology, vol. 154, no. 1, pp. 83–86, 2006. View at Publisher · View at Google Scholar · View at Scopus
  138. A. K. Gupta, M. T. Goldfarb, C. N. Ellis, and J. V. Voorhees, “Side-effect profile of acitretin therapy in psoriasis,” Journal of the American Academy of Dermatology, vol. 20, no. 6, pp. 1088–1093, 1989. View at Google Scholar · View at Scopus
  139. A. Vahlquist and H. Törmä, “Retinoids and keratinization. Current concepts,” International Journal of Dermatology, vol. 27, no. 2, pp. 81–95, 1988. View at Google Scholar · View at Scopus
  140. C. N. Ellis, S. Kang, A. I. Vinik et al., “Glucose and insulin responses are improved in patients with psoriasis during therapy with etretinate,” Archives of Dermatology, vol. 123, no. 4, pp. 471–475, 1987. View at Google Scholar · View at Scopus
  141. T. Ohtsuka, “The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis,” Archives of Dermatological Research, vol. 300, no. 10, pp. 545–550, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. B. E. Strober and K. Menon, “Folate supplementation during methotrexate therapy for patients with psoriasis,” Journal of the American Academy of Dermatology, vol. 53, no. 4, pp. 652–659, 2005. View at Publisher · View at Google Scholar · View at Scopus
  143. M. Soy, M. Yildiz, M. S. Uyanik, N. Karaca, G. Güfer, and S. Piskin, “Susceptibility to atherosclerosis in patients with psoriasis and psoriatic arthritis as determined by carotid-femoral (aortic) pulse-wave velocity measurement,” Revista Española de Cardiología, vol. 62, no. 1, pp. 96–99, 2009. View at Publisher · View at Google Scholar · View at Scopus
  144. Y. Gunes, M. Tuncer, O. Calka et al., “Increased frequency of pulmonary hypertension in psoriasis patients,” Archives of Dermatological Research, vol. 300, no. 8, pp. 435–440, 2008. View at Publisher · View at Google Scholar · View at Scopus
  145. A. Pietrzak, M. Borowik, G. Chodorowska et al., “Lipid profile and serum NT—proBNP level, and disease adaptation in psoriatic patients,” in Sick Person—Biopsychosocial Aspects, K. Janowski and J. Gierus, Eds., pp. 348–360, Wydawnictwo Drukarnia Best Print s.c., Lublin, Poland, 2009. View at Google Scholar
  146. J. Wysocki, S. Skoczyński, A. Strózik, B. Hochuł, and M. Zyguła, “Metabolic or immunometabolic syndrome?” Wiadomosci Lekarskie, vol. 58, no. 1-2, pp. 124–127, 2005. View at Google Scholar · View at Scopus
  147. A. Zalewska, E. Głowacka, J. Wyczółkowska, H. Tchórzewski, J. Narbutt, and A. Sysa-Jědrzejowska, “Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis,” Mediators of Inflammation, vol. 2006, Article ID 81767, 6 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  148. B. D. Edwards, D. Bhatnagar, M. I. Mackness et al., “Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis,” Quarterly Journal of Medicine, vol. 88, no. 2, pp. 109–113, 1995. View at Google Scholar
  149. A. Lassus, A.-L. Dahlgren, M. J. Halpern, J. Santalahti, and H.-P. Happonen, “Effects of dietary supplementation with polyunsaturated ethyl ester lipids (Angiosan) in patients with psoriasis and psoriatic arthritis,” Journal of International Medical Research, vol. 18, no. 1, pp. 68–73, 1990. View at Google Scholar · View at Scopus
  150. H. Meffert, M. Bräutigam, L. Färber, and G. Weidinger, “Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile,” Acta Dermato-Venereologica, vol. 77, no. 2, pp. 137–141, 1997. View at Google Scholar · View at Scopus
  151. J. Miquel, A. Bernd, J. Sempere, J. Díaz-Alperi, and A. Ramírez, “The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review,” Archives of Gerontology and Geriatrics, vol. 34, no. 1, pp. 37–46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  152. A. Osmancevic, L. Nilsen, K. Landin-Wilhelmsen et al., “Effect of climate therapy at Gran Canaria on vitamin D production, blood glucose and lipids in patients with psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 23, no. 10, pp. 1133–1140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  153. F. Reiss and L. Jaimovich, “The influence of sitosterol upon psoriasis vulgaris: observations on electrophoretic pattern,” Dermatologica, vol. 17, no. 5, pp. 393–401, 1958. View at Google Scholar
  154. N. Sattar, P. Crompton, L. Cherry, D. Kane, G. Lowe, and I. B. McInnes, “Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study,” Arthritis and Rheumatism, vol. 56, no. 3, pp. 831–839, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. G. Vallesi, F. Raggi, S. Rufini, S. Gizzi, E. Ercolani, and R. Rossi, “Effects of cyclotronic ion resonance on human metabolic processes: a clinical trial and one case report,” Electromagnetic Biology and Medicine, vol. 26, no. 4, pp. 283–288, 2007. View at Publisher · View at Google Scholar · View at Scopus
  156. I. V. Shrinsky and V. S. Shrinskt, “Efficacy of simvastin in plaque psoriasis: a pilot study,” The Journal of American Academy of Dermatology, vol. 57, no. 3, pp. 529–531, 2007. View at Google Scholar
  157. J. M. Ashley, N. J. Lowe, M. E. Borok, and R. B. Alfin-Slater, “Fish oil supplementation results in decreased hypertriglyceridemia in patients with psoriasis undergoing etretinate or acitretin therapy,” Journal of the American Academy of Dermatology, vol. 19, no. 1 I, pp. 76–82, 1988. View at Google Scholar · View at Scopus
  158. J. R. Marsden, “Effect of dietary fish oil on hyperlipidaemia due to isotretinoin and etretinate,” Human Toxicology, vol. 6, no. 3, pp. 219–222, 1987. View at Google Scholar · View at Scopus
  159. R. M. Grossman, R. J. Delaney, E. A. Brinton, D. M. Carter, and A. B. Gottlieb, “Hypertriglyceridemia in patients with psoriasis treated with cyclosporine,” Journal of the American Academy of Dermatology, vol. 25, no. 4, pp. 648–651, 1991. View at Google Scholar · View at Scopus
  160. E. Cauza, K. Cauza, U. Hanusch-Enserer, M. Etemad, A. Dunky, and K. Kostner, “Intravenous anti TNF-α antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis,” Wiener Klinische Wochenschrift, vol. 114, no. 23-24, pp. 1004–1007, 2002. View at Google Scholar · View at Scopus
  161. C. Antoniou, C. Dessinioti, A. Katsambas, and A. J. Stratigos, “Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-α therapy in a patient with psoriatic arthritis and psoriasis vulgaris,” British Journal of Dermatology, vol. 156, no. 5, pp. 1090–1091, 2007. View at Publisher · View at Google Scholar · View at Scopus
  162. E. Spanakis, P. Sidiropoulos, J. Papadakis et al., “Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab,” Journal of Rheumatology, vol. 33, no. 12, pp. 2440–2446, 2006. View at Google Scholar · View at Scopus
  163. A. N. Rajpara, R. Goldner, and A. Gaspari, “Psoriasis: can statins play a dual role?” Dermatology Online Journal, vol. 16, no. 2, article 2, 2010. View at Google Scholar · View at Scopus
  164. T. C. Jacobi and A. Highet, “A clinical dilemma while treating hypercholesterolaemia in psoriasis,” British Journal of Dermatology, vol. 149, no. 6, pp. 1305–1306, 2003. View at Publisher · View at Google Scholar · View at Scopus